These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 7636535)
1. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. Motzer RJ; Schwartz L; Law TM; Murphy BA; Hoffman AD; Albino AP; Vlamis V; Nanus DM J Clin Oncol; 1995 Aug; 13(8):1950-7. PubMed ID: 7636535 [TBL] [Abstract][Full Text] [Related]
2. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130 [TBL] [Abstract][Full Text] [Related]
3. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Hoffman AD; Engelstein D; Bogenrieder T; Papandreou CN; Steckelman E; Dave A; Motzer RJ; Dmitrovsky E; Albino AP; Nanus DM Clin Cancer Res; 1996 Jun; 2(6):1077-82. PubMed ID: 9816270 [TBL] [Abstract][Full Text] [Related]
4. Effects of retinoic acid and interferon-gamma on expression of the retinoic acid receptor in mouse renal cell carcinoma. Hara I; Taguchi I; Miyake H; Hara S; Gotoh A; Kamidono S Int J Oncol; 2001 Nov; 19(5):959-62. PubMed ID: 11604994 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764 [TBL] [Abstract][Full Text] [Related]
6. Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Berg WJ; Nanus DM; Leung A; Brown KT; Hutchinson B; Mazumdar M; Xu XC; Lotan R; Reuter VE; Motzer RJ Clin Cancer Res; 1999 Jul; 5(7):1671-5. PubMed ID: 10430067 [TBL] [Abstract][Full Text] [Related]
7. Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer. Jacobs A; Gold P; Weiden P; Aboulafia D; Rudolph R; Picozzi V; Thompson J Cancer Invest; 2000; 18(5):417-21. PubMed ID: 10834025 [TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-tumor effect of 13-cRA and IFN-alpha/beta in mouse renal cell carcinoma. Taguchi I; Hara I; Gohji K; Arakawa S; Kamidono S Int J Oncol; 1998 Jul; 13(1):145-9. PubMed ID: 9625816 [TBL] [Abstract][Full Text] [Related]
9. Interaction of retinoic acid and interferon in renal cancer cell lines. Nanus DM; Geng Y; Shen R; Lai HK; Pfeffer SR; Pfeffer LM J Interferon Cytokine Res; 2000 Sep; 20(9):787-94. PubMed ID: 11032398 [TBL] [Abstract][Full Text] [Related]
10. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. Stadler WM; Kuzel T; Dumas M; Vogelzang NJ J Clin Oncol; 1998 May; 16(5):1820-5. PubMed ID: 9586896 [TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066 [TBL] [Abstract][Full Text] [Related]
12. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257 [TBL] [Abstract][Full Text] [Related]
13. 13-cis retinoic acid and interferon alfa-2a in the treatment of metastatic renal cell carcinoma. Casali A; Sega FM; Casali M; Serrone L; Terzoli E J Exp Clin Cancer Res; 1998 Jun; 17(2):227-9. PubMed ID: 9700585 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha]. Paredes Espinoza M; Lippman SM; Kavanagh JJ; Delgadillo Madrueño F; Paredes Casillas P; Bañuelos Acosta O; Alvarez Márquez V; Buenrostro Ahued MA; de Alba Ayala I; Arias Castro G Rev Invest Clin; 1994; 46(2):105-11. PubMed ID: 8052740 [TBL] [Abstract][Full Text] [Related]
15. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495 [TBL] [Abstract][Full Text] [Related]
16. In vitro radiosensitization of human cervical carcinoma cells by combined use of 13-cis-retinoic acid and interferon-alpha2a. Ryu S; Kim OB; Kim SH; He SQ; Kim JH Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):869-73. PubMed ID: 9652851 [TBL] [Abstract][Full Text] [Related]
17. A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers. Dunst J; Hänsgen G; Krause U; Füchsel G; Köhler U; Becker A Strahlenther Onkol; 1998 Nov; 174(11):571-4. PubMed ID: 9830438 [TBL] [Abstract][Full Text] [Related]
18. All-trans retinoic acid and interferon-alpha for treatment of human renal cell carcinoma multicellular tumor spheroids. Rohde D; Brkovic D; Hönig d'Orville I Urol Int; 2004; 73(1):47-53. PubMed ID: 15263793 [TBL] [Abstract][Full Text] [Related]
19. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon. Dunst J; Hänsgen G; Lautenschläger C; Füchsel G; Becker A Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):367-73. PubMed ID: 10030263 [TBL] [Abstract][Full Text] [Related]
20. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]